---
schema_version: "secwatch.filing_event.v1"
accession: "0000010795-24-000044"
form_type: "8-K"
ticker: "BDX"
cik: "0000010795"
company_name: "BECTON DICKINSON & CO"
filed_at: "2024-06-03T23:59:59+00:00"
generated_at: "2026-06-01T06:43:16.343415+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# BD to acquire Edwards Lifesciences' Critical Care for $4.2B in cash

## Summary
- Acquisition price of $4.2B in cash; expected to close by end of calendar 2024, subject to regulatory approvals.
- Critical Care generated >$900M revenue in 2023; BD expects 6-7% growth, >60% adjusted gross margin, >25% adjusted operating margin.
- Funded with ~$1B cash and ~$3.2B new debt; net leverage ~3x at close, targeting 2.5x within 12-18 months via free cash flow.
- Transaction immediately accretive to BD revenue growth, adjusted gross/operating margins, and adjusted EPS.
- Critical Care to operate as separate business unit within BD Medical, led by Katie Szyman, based in Irvine, CA.

## SEC filing metadata
- accession: 0000010795-24-000044
- form_type: 8-K
- ticker: BDX
- cik: 0000010795
- company_name: BECTON DICKINSON & CO
- filed_at: 2024-06-03T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/10795/000001079524000044/0000010795-24-000044-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/10795/000001079524000044/bdx-20240603.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000010795-24-000044
- JSON: https://secwatch.observer/filing/0000010795-24-000044.json
- Plain text: https://secwatch.observer/filing/0000010795-24-000044.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.